Company Focus
Gilead Sciences
Latest Gilead Sciences News
Biotechnology
USA-based biotech company Prolynx has expanded its senior leadership, appointing Simon Harnest as chief financial officer and Amer Mirza as chief scientific officer, as the Emeryville, California, firm pushes a portfolio of long-acting obesity and metabolic disease candidates toward first-in-human testing. 16 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing gedatolisib, a pan-PI3K/mTORC1/2 inhibitor targeting the PAM pathway across multiple solid tumor indications, with pivotal Phase III data now in hand.
Latest News & Features of interest to Gilead Sciences
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Biotechnology
Canadian genetic medicines company enGene Therapeutics announced changes to its board of directors as it prepares for potential regulatory milestones and commercial readiness for its investigational gene therapy, detalimogene voraplasmid, if approved. 17 July 2026
Biotechnology
China’s Kelun-Biotech reported that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with Merck & Co’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda (pembrolizumab) has met its primary endpoint of progression free survival (PFS) at a prespecified interim analysis. 17 July 2026
Biosimilars
Shilpa Biologicals, part of India’s Shilpa Medicare, has entered into a co-development and supply agreement with Finnish drugmaker Orion Corporation for a nivolumab biosimilar. 16 July 2026
Biotechnology
The Russian Ministry of Health has officially registered a new drug for the treatment of lymphoma. The drug from Swiss company Swixx Biopharma, which is marketed under the Mindzhuvi, becomes the first drug containing tafasitamab on the Russian market. 16 July 2026
Biotechnology
Rare disease company Swedish Orphan Biovitrum (Sobi) raised its full-year guidance after reporting strong second-quarter growth, led by its hematology and immunology franchises. 16 July 2026
Pharmaceutical
Family-owned German pharma major Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the USA due to increased demand for Jardiance (empagliflozin tablets) and successful new launches. 16 July 2026
Biotechnology
USA-based biotech company Prolynx has expanded its senior leadership, appointing Simon Harnest as chief financial officer and Amer Mirza as chief scientific officer, as the Emeryville, California, firm pushes a portfolio of long-acting obesity and metabolic disease candidates toward first-in-human testing. 16 July 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory agency (MHRA) has granted marketing authorization for Johnson & Johnson’s Akeega (niraparib and abiraterone acetate dual-action pill), with prednisone or prednisolone, in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) and BRCA1/2 mutations (germline and/or somatic). 16 July 2026
Biotechnology
Australian radiopharmaceutical company AdvanCell has closed an oversubscribed and upsized $315 million Series D financing to advance its targeted alpha therapy pipeline and expand its manufacturing network. 15 July 2026
Latest In Brief for Gilead Sciences
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze